833 | PRO‐MIND: PROSPECTIVE REAL‐WORLD STUDY OF TAFASITAMAB PLUS LENALIDOMIDE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN ITALY—AN ONGOING TRIAL

Documenti analoghi

• 234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
  di: L. H. Sehn, et al.
  Pubblicazione: (2025)
• 439 | ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
  di: Z. Song, et al.
  Pubblicazione: (2025)
• 28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
  di: L. H. Sehn, et al.
  Pubblicazione: (2025)
• 636 | GLOFITAMAB COMBINED WITH SALVAGE THERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A REAL‐WORLD PROSPECTIVE OBSERVATIONAL STUDY IN CHINESE PATIENTS
  di: H. Huang
  Pubblicazione: (2025)
• 666 | OUTCOMES OF RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN AN ASIAN MULTIETHNIC COHORT
  di: N. Lim, et al.
  Pubblicazione: (2025)